A Phase II Study of R-FND, Followed by Zevalin Radioimmunotherapy, and Subsequent Maintenance Rituximab for Advanced Stage Follicular Lymphoma With High-Risk Features

Trial Profile

A Phase II Study of R-FND, Followed by Zevalin Radioimmunotherapy, and Subsequent Maintenance Rituximab for Advanced Stage Follicular Lymphoma With High-Risk Features

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Dec 2016

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Rituximab (Primary) ; Dexamethasone; Dexamethasone; Fludarabine; Mitoxantrone
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Dec 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 18 Dec 2015 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov.
    • 18 Dec 2014 Planned primary completion date changed from 1 Jun 2015 to 1 Jun 2016, according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top